

Lexaria Bioscience Corp.  
Form 8-K  
January 28, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **January 28, 2019**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

<b>Nevada</b> (State or other jurisdiction of incorporation)	<b>000-52138</b> (Commission File Number)	<b>20-2000871</b> (IRS Employer Identification No.)
--	---	---

**100 – 740 McCurdy Road, Kelowna, BC**  
**Canada**  
(Address of principal executive offices)

**V1X 2P7**  
(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

**156 Valleyview Road, Kelowna, BC Canada V1X 3M4**

Edgar Filing: Lexaria Bioscience Corp. - Form 8-K

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item Unregistered Sales of Equity Securities  
3.02**

Lexaria has received US\$108,000 from the exercise of 180,000 warrants at the exercise price of US\$0.60 previously granted to third parties who are neither officers nor directors of the Company and has issued 180,000 common shares as a result. Lexaria has also issued 100,000 restricted common shares at an issue price of US\$1.31 as required by a consulting agreement.

No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

**The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements**

**Item Regulation FD Disclosure  
7.01**

A copy of the news release announcing the exercise of warrants previously granted and the issuance of shares pursuant to a services agreement is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

**Item Financial Statements and Exhibits  
9.01**

99.1 Press Release dated January 25, 2019

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

*/s/ Chris Bunka*

**Chris Bunka**

CEO, Principal Executive Officer

Date: January 28, 2019